Stockscreener 앱 받기
19.93
11.66%
-2.63
시장 영업 전:
20.20
0.27
+1.35%
Zenas Biopharma Inc 주식(ZBIO)의 최신 뉴스
Zenas BioPharma, Inc. (ZBIO) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Shareholders to Contact the Firm to Learn More About the Investigation - ACCESS Newswire
Zenas BioPharma (NASDAQ:ZBIO) Stock Price Down 7.1%Time to Sell? - MarketBeat
Zenas BioPharma Stock Pre-Market (-4.4%): Shareholder Lawsuit Investigation Announced - Trefis
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Zenas BioPharma, Inc.ZBIO - Chartmill
Bronstein, Gewirtz & Grossman, LLC Is Investigating Zenas BioPharma, Inc. (ZBIO) And Encourages Investors to Connect - ACCESS Newswire
Assessing Zenas BioPharma (ZBIO) Valuation After Phase 3 INDIGO Success And CEO Share Purchase - Sahm
Assessing Zenas BioPharma (ZBIO) Valuation After Positive INDIGO Phase 3 Trial News - Yahoo Finance
Zenas BioPharma (NASDAQ:ZBIO) Shares Gap Up After Insider Buying Activity - MarketBeat
Sunday’s Insider Activity: Big Buys at Zenas, Hycroft, and Major NVDA Sell By Investing.com - Investing.com South Africa
Sunday’s Insider Activity: Big Buys at Zenas, Hycroft, and Major NVDA Sell - Investing.com
Ideas Watch: What are Zenas BioPharma Incs technical support levelsQuarterly Profit Report & Advanced Swing Trade Entry Plans - baoquankhu1.vn
Insider Stock Purchases: January 10, 2026 - Quiver Quantitative
Zenas BioPharma Stock (ZBIO) Opinions on INDIGO Trial Results and CEO Investment - Quiver Quantitative
Zenas BioPharma (NASDAQ:ZBIO) CEO Buys $819,000.00 in Stock - MarketBeat
Insider Buying: Zenas BioPharma (NASDAQ:ZBIO) CEO Acquires 30,000 Shares of Stock - MarketBeat
Leon Moulder Jr Acquires 20,000 Shares of Zenas BioPharma (NASDAQ:ZBIO) Stock - MarketBeat
Zenas Biopharma (ZBIO) CEO Moulder buys $1.63m in stock By Investing.com - Investing.com South Africa
Zenas Biopharma (ZBIO) CEO Moulder buys $1.63m in stock - Investing.com
Zenas BioPharma, Inc. (ZBIO) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Stockholders to Contact the Firm to Learn More About the Investigation - ACCESS Newswire
Does Zenas BioPharma (ZBIO) Pair INDIGO Success With Manageable China-Linked Risks In Its Strategy? - Sahm
Why Zenas BioPharma Inc. stock is favored by top institutionsJuly 2025 Analyst Calls & Long Hold Capital Preservation Plans - Улправда
What insider trading reveals about Zenas BioPharma Inc. stock2025 Technical Overview & Consistent Income Trade Recommendations - Улправда
Will Zenas BioPharma Inc. stock benefit from upcoming earnings reportsWeekly Investment Recap & Safe Investment Capital Preservation Plans - ulpravda.ru
Will Zenas BioPharma Inc. stock reach Wall Street targetsRisk Management & Reliable Momentum Entry Alerts - Улправда
Is Zenas BioPharma Inc. stock a bargain at current levels2025 Price Momentum & Weekly High Momentum Picks - Улправда
Zenas BioPharma Shares Phase III INDIGO Win as Obexelimab Cuts IgG4-RD Flare Risk 56% - MarketBeat
ZBIO tanks despite positive data from rare autoimmune diseases study - MSN
Bronstein, Gewirtz & Grossman, LLC Encourages Zenas BioPharma, Inc. (ZBIO) Investors to Inquire about Securities Investigation - ACCESS Newswire
Zenas BioPharma (NASDAQ:ZBIO) Trading Up 11%Here's Why - MarketBeat
Zenas BioPharma Touts Phase 3 Win, But Stock Crashes - Yahoo Finance UK
ZBIO Tanks Despite Positive Data From Rare Autoimmune Diseases Study - sharewise.com
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Zenas BioPharma, Inc. (ZBIO) and Encourages Stockholders to Learn More About the Investigation - ACCESS Newswire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Zenas ... - Bluefield Daily Telegraph
Morgan Stanley Downgrades Zenas BioPharma (ZBIO) Rating and Pric - GuruFocus
Zenas BioPharma (NASDAQ:ZBIO) Trading Down 15.5% Following Analyst Downgrade - MarketBeat
Zenas BioPharma stock slides again premarket after INDIGO Phase 3 data sparks fresh scrutiny - TechStock²
Zenas’s Obexelimab Meets Phase III Endpoint In IgG4-RD But Trails Amgen Rival - Citeline News & Insights
Zenas Biopharma stock maintains Buy rating at H.C. Wainwright after positive trial data - Investing.com Canada
Why Zenas BioPharma's Selloff Was Structurally Inevitable - Benzinga
Zenas’ stock drops 51% despite lead asset’s Phase III rare disease win - Yahoo Finance
Jefferies lowers Zenas Biopharma stock price target to $48 on trial data - Investing.com Canada
Why Is ZBIO Stock Falling Pre-Market Today? - Stocktwits
Zenas: Maintaining 'Strong Buy' As Cross-Trial Comparison Of Obexelimab Should Not Be A Factor - Seeking Alpha
How Much Could Obexelimab’s Phase 3 Win Reshape Zenas BioPharma’s (ZBIO) Autoimmune Franchise Ambitions? - Yahoo Finance
Zenas BioPharma Stock Pre-Market (-4.0%) : Fallout From Phase 3 Data Disappointment - Trefis
Zenas BioPharma’s immune disorder drug meets main goal in late-stage trial - WHTC
Zenas BioPharma's immune disorder drug meets main goal in late-stage trial - ET Pharma
A Look At Zenas BioPharma (ZBIO) Valuation After Recent Volatility And Premium Price To Book Ratio - Sahm
Zenas Biopharma stock rating downgraded by Morgan Stanley on trial results - Investing.com Canada
Zenas BioPharma, A Top 1% Stock, Quadrupled In 2025. Why It Just Collapsed. - Investor's Business Daily
Zenas BioPharma (NASDAQ:ZBIO) Downgraded to "Equal Weight" Rating by Morgan Stanley - MarketBeat
Zenas BioPharma Stock Plummets 57% Despite Positive Phase 3 INDIGO Results - Nasdaq
Citi trims Zenas BioPharma target, calls pullback on INDIGO an ‘overreaction’ - TipRanks
Zenas BioPharma (NASDAQ:ZBIO) Shares Gap DownHere's Why - MarketBeat
Obexelimab’s Strong Phase 3 Data and Differentiated Positioning Underpin Zenas BioPharma Buy Rating and $44 Target - TipRanks
Zenas Bio Inflammation Drug Meets Phase 3 Goals, But Is It Enough to Compete With Amgen? - MedCity News
Zenas BioPharma announces positive phase 3 Obexelimab results - MSN
Indigo grills: Street querying Zenas phase III IgG4-RD beat - BioWorld MedTech
Zenas shares crash after top drug misses expectations in immune disease study - BioPharma Dive
Zenas shares plunge on weaker-than-expected data for immune disorder drug - marketscreener.com
0.67%
1.69%
자본화:
|
볼륨(24시간):